Farallon Capital Management LLC Takes $100.94 Million Position in Teva Pharmaceutical Industries Ltd. $TEVA

Farallon Capital Management LLC acquired a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 4,997,000 shares of the company’s stock, valued at approximately $100,939,000. Farallon Capital Management LLC owned about 0.44% of Teva Pharmaceutical Industries as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Advisors Asset Management Inc. purchased a new stake in Teva Pharmaceutical Industries during the second quarter valued at about $41,000. Cromwell Holdings LLC raised its holdings in shares of Teva Pharmaceutical Industries by 40.3% in the 3rd quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock worth $44,000 after purchasing an additional 629 shares during the period. MAI Capital Management raised its holdings in shares of Teva Pharmaceutical Industries by 26.8% in the 2nd quarter. MAI Capital Management now owns 3,293 shares of the company’s stock worth $55,000 after purchasing an additional 697 shares during the period. Rothschild Investment LLC lifted its stake in shares of Teva Pharmaceutical Industries by 97.0% in the 3rd quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock valued at $55,000 after purchasing an additional 1,348 shares in the last quarter. Finally, JFS Wealth Advisors LLC lifted its stake in shares of Teva Pharmaceutical Industries by 257.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company’s stock valued at $56,000 after purchasing an additional 2,000 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $28.54 on Monday. The firm has a market cap of $32.81 billion, a P/E ratio of 23.78, a price-to-earnings-growth ratio of 9.56 and a beta of 0.72. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $37.35. The stock has a 50-day simple moving average of $32.91 and a 200-day simple moving average of $26.74.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping the consensus estimate of $0.65 by $0.31. The firm had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.Teva Pharmaceutical Industries’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, equities analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

TEVA has been the subject of a number of research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, January 21st. Barclays lifted their price target on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a research report on Friday, January 30th. Jefferies Financial Group boosted their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. The Goldman Sachs Group increased their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Finally, Bank of America raised their target price on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $37.67.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 77,400 shares of the business’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $30.24, for a total transaction of $2,340,576.00. Following the transaction, the director directly owned 367,600 shares of the company’s stock, valued at approximately $11,116,224. The trade was a 17.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Richard D. Francis sold 442,935 shares of the company’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $32.36, for a total transaction of $14,333,376.60. Following the completion of the transaction, the chief executive officer owned 642,099 shares of the company’s stock, valued at $20,778,323.64. This trade represents a 40.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 948,499 shares of company stock valued at $30,897,071. 0.55% of the stock is owned by company insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.